Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.

MLA

Goldschmidt, Neta, et al. “Addition of High-Dose Methotrexate to Standard Treatment for Patients with High-Risk Diffuse Large B-Cell Lymphoma Contributes to Improved Freedom from Progression and Survival but Does Not Prevent Central Nervous System Relapse.” Leukemia & Lymphoma, vol. 60, no. 8, Aug. 2019, pp. 1890–98. EBSCOhost, https://doi.org/10.1080/10428194.2018.1564823.

APA

Goldschmidt, N., Horowitz, N. A., Heffes, V., Darawshy, F., Mashiach, T., Shaulov, A., Gatt, M. E., & Dann, E. J. (2019). Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse. Leukemia & Lymphoma, 60(8), 1890–1898. https://doi.org/10.1080/10428194.2018.1564823

Chicago

Goldschmidt, Neta, Netanel A Horowitz, Vered Heffes, Fares Darawshy, Tatiana Mashiach, Adir Shaulov, Moshe E Gatt, and Eldad J Dann. 2019. “Addition of High-Dose Methotrexate to Standard Treatment for Patients with High-Risk Diffuse Large B-Cell Lymphoma Contributes to Improved Freedom from Progression and Survival but Does Not Prevent Central Nervous System Relapse.” Leukemia & Lymphoma 60 (8): 1890–98. doi:10.1080/10428194.2018.1564823.